Ipca Laboratories Ltd
IPCALABBSE 524494PharmaceuticalsMkt cap ₹49,219 Cr
Whole group, including subsidiaries — the figures companies headline.
Revenue · Q1 FY27
₹2,788 Cr
YoY +20.8%QoQ +16.7%
Net profit · Q1 FY27
₹424 Cr
YoY +82.2%QoQ +38.3%
Net margin · Q1 FY27
15.2%
+5.1 pts vs Q1 FY26
Net profit · FY26
₹1,184 Cr
YoY +50.8%
Quarterly results
| ₹ Cr | Q1 FY27 Apr–Jun 2026 | Q4 FY26 Jan–Mar 2026 | Q3 FY26 Oct–Dec 2025 | Q2 FY26 Jul–Sep 2025 | Q1 FY26 Apr–Jun 2025 | YoY |
|---|---|---|---|---|---|---|
| Revenue | 2,788 | 2,388 | 2,393 | 2,557 | 2,309 | +20.8% |
| Other income | 25.26 | 93.74 | 20.19 | 27.86 | 32.66 | -22.7% |
| Total income | 2,813 | 2,482 | 2,413 | 2,584 | 2,342 | +20.2% |
| Profit before tax | 572 | 404 | 446 | 392 | 331 | +73.1% |
| Tax | 149 | 95.05 | 81.93 | 108 | 96.09 | +55.3% |
| Net profit | 424 | 307 | 364 | 281 | 233 | +82.2% |
| Net margin | 15.2% | 12.8% | 15.2% | 11.0% | 10.1% |
Annual results
| ₹ Cr | FY26 Apr 2025–Mar 2026 | FY25 Apr 2024–Mar 2025 | FY24 Apr 2023–Mar 2024 | FY23 Apr 2022–Mar 2023 | FY22 Apr 2021–Mar 2022 | YoY |
|---|---|---|---|---|---|---|
| Revenue | 9,646 | 8,940 | 7,705 | 6,244 | 5,830 | +7.9% |
| Other income | 174 | 92.80 | 125 | 126 | 66.57 | +88.0% |
| Total income | 9,821 | 9,032 | 7,830 | 6,370 | 5,896 | +8.7% |
| Profit before tax | 1,573 | 1,131 | 843 | 745 | 1,136 | +39.0% |
| Tax | 381 | 344 | 313 | 253 | 224 | +10.9% |
| Net profit | 1,184 | 785 | 523 | 479 | 890 | +50.8% |
| Net margin | 12.3% | 8.8% | 6.8% | 7.7% | 15.3% |
BIC's take
We haven't covered Ipca Laboratories Ltd yet. Browse our sector reports →
Source: BSE filings · Data as of 2 Oct 2026, 5:12 pm IST· ₹ crore unless stated. Covers BSE 500 companies only. Consolidated figures include subsidiaries; standalone is the parent company alone. Growth is shown only against a positive base. Not investment advice — check the company's full filing before acting.